Cervical cancer is the disease that happens due to formation of malignant cells in the cervix. Human papillomavirus (HPV) is the major risk factor for cervical cancer. Women aged 30 to 45 years are at high risk of developing the disease. Squamous cell carcinoma and adenocarcinoma are the major types of cervical cancer. Pap smear test, HPV tests are the most common test used for the detection of cervical cancer in females.

Adroit Market Research study on the global market for cervical cancer diagnostics offers a holistic view of the industry from 2020 to 2028 as forecast period, including factors such as market drivers, limitations, opportunities, threats and regulatory overview. The market has been analyzed from 2018 to 2028, with a base year estimate of 2019 and a projection from 2020 to 2028. The report covers the current status and potential characteristics of the market at both the global and the country level. Moreover, the report also assesses market competition with Porter's analysis of five strengths and places leading players on the basis of their product range, regional presence, strategic initiatives and overall sales. Prominent players in the global cervical cancer diagnostics market have been analyzed in depth.

High prevalence and increasing incidence of cervical cancer worldwide increases the demand for early detection and treatment and positively impacts growth of the market. According to Globocan, there were 604,127 new cases of cervical cancer along with 341,831 deaths across the globe, as of November 2020. However, changing regulatory policies for cervical cancer screening is a major factor hampering the growth of the cervical cancer diagnostics market.

Pap smear test segment will hold substantial share of the global cervical cancer diagnostics market. The Pap smear test has become popular test for screening of cervical cancer. However, increase in HPV infections among females will drive the demand for HPV tests in the next few years. Hospitals, laboratories, diagnostic centers & clinics carry out these screening tests for early detection of cervical cancer.

North America held dominant share of the global cervical cancer diagnostics market owing to presence of large target population suffering from cervical cancer in the U.S. and Canada. Moreover, favorable government initiatives for cervical cancer screening along with high incidence of HPV infections is expected to fuel market growth for cervical cancer diagnostics in the next few years. Asia Pacific is expected to witness lucrative growth over the forecast timeframe. This is attributable to rise in prevalence of cervical cancer along with presence of large geriatric population across various emerging countries such as China and India.

key players operating in the global cervical cancer diagnostics market include F. Hoffmann-La Roche Ltd., Abbott Molecular, Quest Diagnostics, Inc., Becton, Dickinson and Company, QIAGEN, OncoHealth Corporation, Hologic Inc., CooperSurgical, Inc., and Arbor Vita Corporation among others.

Key Segments of the Global Cervical Cancer Diagnostics Market

Test Type Overview, 2018-2028 (USD Million)

• Pap Smear Test
• HPV Test
• Cervical Biopsies
• Cystoscopy

End-user Overview, 2018-2028 (USD Million)

• Hospitals
• Diagnostic Centers
• Others

Regional Overview, 2018-2028 (USD Million)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa